Cardiovascular Systems (CSII) – StreetInsider.com Reports
-
Cytek Biosciences (CTKB) to join S&P SmallCap 600
-
Abbott (ABT) acquires Cardiovascular Systems (CSII) in 'brilliant move'
-
Cardiovascular Systems (CSII) PT Raised to $20 at Stifel
-
Lake Street Capital Markets Downgrades Cardiovascular Systems (CSII) to Sell
-
Abbott (ABT) to acquire Cardiovascular Systems (CSII) for $20/share
-
Cardiovascular Systems (CSII) Misses Q2 EPS by 5c
-
Cardiovascular Systems (CSII) Announces FDA 510(k) Submission of Innova Vascular, Inc.’s Thrombectomy System
-
Barclays Starts Cardiovascular Systems (CSII) at Equalweight
-
Lake Street Capital Markets Starts Cardiovascular Systems (CSII) at Buy
-
Cardiovascular Systems (CSII) Announces Full Market Release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems
-
Nephron Starts Cardiovascular Systems (CSII) at Hold
-
Stifel Reiterates Hold Rating on Cardiovascular Systems (CSII) Following COO Departure
-
Cardiovascular Systems (CSII) PT Lowered to $30 at Oppenheimer
-
Cardiovascular Systems (CSII) Tops Q3 EPS by 3c
-
Cardiovascular Systems (CSII) Expands into 4 Areas, Increasing Spending and Creating Call Options - Oppenheimer
-
Cardiovascular Systems (CSII) Appoints Jeffery W. Chambers as CMO
-
UPDATE: BofA Securities Reinstates Cardiovascular Systems (CSII) at Underperform
-
Cardiovascular Systems (CSII) PT Lowered to $18 at Stifel, Following Earnings
-
Cardiovascular Systems (CSII) PT Lowered to $34 at Oppenheimer
-
Cardiovascular Systems (CSII) Misses Q2 EPS by 10c
-
Cardiovascular Systems (CSII) and OrbusNeich Announce FDA PMA Approval of Scoreflex Scoring Balloon
-
Cardiovascular Systems (CSII) Announces Development of Intravascular Lithotripsy Technology for the Treatment of Coronary and Peripheral Artery Diseases
-
Oppenheimer Defending Cardiovascular Systems (CSII), Sees 100% Upside
-
Cardiovascular Systems (CSII) Announces Voluntary Recall of WIRION
-
UPDATE: Needham & Company Downgrades Cardiovascular Systems (CSII) to Hold
-
Cardiovascular Systems (CSII) PT Lowered to $39 at Northland Capital Markets
-
Guggenheim Downgrades Cardiovascular Systems (CSII) to Neutral
-
Cardiovascular Systems (CSII) PT Lowered to $32 at Stifel, Following Earnings
-
Cardiovascular Systems (CSII) PT Lowered to $49 at Needham & Company
-
Cardiovascular Systems (CSII) Tops Q4 EPS by 3c
-
UPDATE: Barclays Starts Cardiovascular Systems (CSII) at Equalweight
-
Cardiovascular Systems (CSII) Misses Q3 EPS by 5c
-
Cardiovascular Systems (CSII) Announces Investment and Acquisition Option Agreement With Telehealth Company, CarePICS, LLC
-
Cardiovascular Systems (CSII) Announces Acquisition of Peripheral Support Catheters From WavePoint Medical, LLC
-
Cardiovascular Systems (CSII) PT Raised to $48 at Oppenheimer
-
Cardiovascular Systems (CSII) PT Raised to $50 at Needham & Company
-
Cardiovascular Systems (CSII) PT Raised to $43 at Stifel
-
Cardiovascular Systems (CSII) Tops Q2 EPS by 6c, Revenues Miss; Offers 3Q Revenue Guidance Below Consensus
-
Cardiovascular Systems (CSII) Adds Sachin H. Jain, MD, MBA to Board
-
Cardiovascular Systems (CSII) PT Raised to $50 at SVB Leerink
-
Cardiovascular Systems (CSII) PT Raised to $47 at Needham & Company
-
Cardiovascular Systems (CSII) Tops Q1 EPS by 17c
-
Cardiovascular Systems (CSII) PT Lowered to $40 at Stifel, Following Earnings
-
Cardiovascular Systems (CSII) Tops Q4 EPS by 3c
-
Northland Capital Markets Starts Cardiovascular Systems (CSII) at Outperform
-
Barclays Starts Cardiovascular Systems (CSII) at Overweight
-
Aegis Capital Starts Cardiovascular Systems (CSII) at Buy, Earlier Today
-
UPDATE: Needham & Company Upgrades Cardiovascular Systems (CSII) to Buy
-
Pre-Open Stock Movers 06/10: (LAKE) (TRUE) (FIVE) Higher; (TCO) (HTZ) (GES) Lower (more...)
-
Cardiovascular Systems (CSII) Prices 3.676M Share Common Offering at $34/Sh
Back to CSII Stock Lookup